Key Stats for UNH Stock
- Past week’s performance: -2%
- 52-week range: $244 to $462
- Valuation model target price: $504
- Implied upside: 24.7% over 2.4 years
See what UnitedHealth’s margin recovery could mean for its long-term valuation (It’s free) >>>
Medical Costs Finally Cooperate, and Guidance Moves Higher
UnitedHealth (UNH) shares have climbed sharply since the company’s July 16 earnings report, even though broader healthcare sentiment cooled slightly this week. The company posted second quarter revenue of about $112 billion and adjusted earnings per share of $6.38, both ahead of expectations.
The number investors care about most is the medical care ratio, which measures how much of premium revenue goes toward paying medical claims. That ratio improved to 86.7%, down 270 basis points from a year earlier. Lower medical costs directly translate into higher profit, and that shift helped UnitedHealthcare’s operating margin nearly double to 4.6%.
Optum, the company’s health services division, also showed improvement, with its operating margin rising to 6.2%. Because Optum spans pharmacy benefits, care delivery, and data analytics, its recovery signals that the broader UnitedHealth business is stabilizing, not just the insurance side.
If this cost trend continues through the back half of the year, the raised guidance looks achievable rather than aspirational. Management raised full-year adjusted EPS guidance to a range of $19.50 to $20.00 and doubled its planned share repurchase authorization to at least $5 billion, a strong signal of confidence in the recovery.
Estimate UnitedHealth’s fair value based on where medical costs settle from here (It’s free) >>>
Is UNH Stock Undervalued After the Bounce?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue Growth (CAGR): 2.8%
- Operating Margins: 6.3%
- Exit P/E Multiple: 18.4x
Based on these inputs, the model estimates a target price of $504, implying a 24.7% total return and a 9.6% annualized return over the next 2.4 years.
UnitedHealth still trades well below its own 52-week high of $462, so the recovery story remains only partially priced in. The model assumes modest revenue growth near 3%, reflecting how much smaller UnitedHealth’s insurance premium increases have become compared to its historical double-digit pace.
Margin recovery is really the whole thesis here. A 6.3% operating margin assumption is still below the company’s five-year average near 8.7%, which suggests the model is not pricing in a full return to prior profitability levels. If medical costs keep improving, there is room for margins to climb further than the current forecast assumes.
Planned AI investments across claims processing and care management could support additional cost savings over time. That is a supporting factor, not the primary driver, since the immediate catalyst remains the medical cost trend and the raised earnings outlook.
Estimate a company’s fair value instantly (Free with TIKR) >>>
UnitedHealth vs CVS Health and Cigna in Managed Care
UnitedHealth’s rebound looks even more notable next to how its peers are performing. CVS Health (CVS) and Cigna (CI) offer useful benchmarks for how the broader managed care sector is trading right now.
CVS trades at a forward P/E closer to 12x, and while it recently raised its own profit forecast on improved drug revenue, its stock reaction was more muted than UnitedHealth’s July surge. Its operating margins remain in the low single digits, similar to where UnitedHealth sat before its recent improvement.
Cigna trades at a forward P/E near 11x and has leaned into AI tools, projecting $200 million in customer savings over three years. Cigna’s revenue growth has been running in the low single digits, comparable to UnitedHealth’s own modest pace.
UnitedHealth’s scale advantage, spanning insurance, pharmacy benefits, and care delivery through Optum, gives it more levers to pull for margin improvement than either CVS or Cigna. That diversification is a key part of why investors rewarded UnitedHealth’s earnings beat so aggressively.
See how Medicare Advantage pricing and medical-cost trends shape UNH’s earnings recovery >>>
What’s Driving UNH Stock Going Forward?
The raised 2026 guidance range of $19.50 to $20.00 in adjusted EPS is the clearest forward catalyst. Every future earnings report will be measured against whether the company is tracking toward that range, and any signs of slippage could quickly reverse recent gains.
Capital returns are another theme worth watching. Doubling the share repurchase authorization to at least $5 billion signals management’s confidence, and continued buybacks could provide support for the stock even if sentiment around healthcare stays choppy.
AI-driven cost savings represent a longer-term catalyst rather than an immediate one. If UnitedHealth can meaningfully reduce administrative and claims processing costs through AI tools, that would reinforce the margin recovery story already underway.
If medical cost trends hold steady into 2027, the current valuation gap versus UnitedHealth’s historical multiple could continue narrowing. Investors should watch third quarter results for confirmation that the July improvement was not a single quarter anomaly.
See how UnitedHealth’s margin recovery could play out over the next few years >>>
Should You Invest in UnitedHealth?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up UNH, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track UNH alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze UNH stock on TIKR Free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
